Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burroni

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Blood|July 29, 2025
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndromePaul Breillat, Francesco Carbone, Emilie Lereclus, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
The Lancet. Haematology|June 4, 2026
Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation studyMarie Donzel, Syrine Khedimallah, Sabrina Barriere, et al.
Blood Advances|March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM studyDamien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2025
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelinesLoïc Renaud, Marie Donzel, Justine Decroocq, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Blood|July 29, 2025
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndromePaul Breillat, Francesco Carbone, Emilie Lereclus, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
The Lancet. Haematology|June 4, 2026
Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation studyMarie Donzel, Syrine Khedimallah, Sabrina Barriere, et al.
Blood Advances|March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM studyDamien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2025
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelinesLoïc Renaud, Marie Donzel, Justine Decroocq, et al.
Pageof 6